ClinicalTrials.gg
CompletedNCT01272180Updated Jun 16, 2020Results posted

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

A Phase 2 interventional study of Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. and Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. in Invasive Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 13 sites in 2 countries. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-16.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
484
Allocation
Randomized
Ages
10 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Meningococcal Infections by Novartis — none open to participants now, none under way, none of them phase 3. Meningococcal Infections · Novartis.

Enrollment
29th of 57
484 · median 484
Started
2011
with 9 others
Phase 2
21 of 60
none open now
Registered
39th of 60
by date

Among the 60 studies in Meningococcal Infections by Novartis, this one is the 29th largest by enrollment of the 57 interventional ones that give a count, is one of 10 that started in 2011, is one of 21 in phase 2, and was the 39th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

None of the 60 studies in Meningococcal Infections by Novartis is open now. The open studies under Meningococcal Infections, anywhere →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 10 Years to 25 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 60 studies in Meningococcal Infections by Novartis as a file.
02

Study summary

This study will evaluate the safety and immunogenicity of combination vaccines as compared to the reference vaccines

03

Conditions studied

  • Invasive Meningococcal Disease

Keywords

  • Safety
  • Immunogenicity
  • Vaccine
  • Meningococcal
  • Seroresponse
04

Who can participate

Ages eligible
10 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adolescents aged 10 through 25 years of age inclusive at the time of enrollment.

Exclusion criteria

Exclusion Criteria:

  • History of any meningococcal vaccine administration;
  • Current or previous, confirmed or suspected disease caused by N. meningitidis;
  • Pregnant or nursing (breastfeeding) mothers;
  • Females of childbearing age who have not used or do not plan to use acceptable measures, for the duration of the study;
  • Any serious, chronic, or progressive disease;
  • Known or suspected impairment/alteration of the immune system;
  • Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;
  • History of severe allergic reactions after previous vaccinations or to any vaccine component.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
484 participants (actual)

Study arms

  • Experimental
    ABCWY+OMV

    Subjects in this group received two doses of "Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine" plus Outer Membrane Vesicles (OMV) administered two months apart.

    Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.

  • Experimental
    ABCWY+qOMV

    Subjects in this group received two doses of "Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine" plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart.

    Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.

  • Active comparator
    rMenB+OMV

    Subjects in this group received two doses of "Meningococcal (group B) multicomponent recombinant adsorbed vaccine",administered two months apart.

    Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.

  • Active comparator
    MenACWY

    Subjects in this group received a dose of placebo followed by one dose of "Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine" administered two months later.

    Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.

Interventions

  • BiologicalMeningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.

    Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.

  • BiologicalMeningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.

    Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.

  • BiologicalMeningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.

    One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.

  • BiologicalMeningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.

    Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.

06

What researchers measure

Primary outcomes

  1. Percentages of Subjects With a Seroresponse Against N.Meningitidis Serogroups A,C,W-135,Y, After Receiving Different Formulations of MenABCWY Combination Vaccine.

    Non-inferiority of immune response of two doses of two different formulations of MenABCWY vaccine to a single dose of MenACWY vaccine as measured by the percentage of subjects with hSBA seroresponse against N.meningitidis serogroups A,C,W and Y. Seroresponse is defined as: 1. For subjects with a pre-vaccination hSBA titer \< 1:4, a post-vaccination hSBA titer ≥ 1:8; 2. For subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the prevaccination titer. Functional bactericidal antibodies directed against serogroups A,C,W,Y meningococci were measured with a serum bactericidal activity assay using human serum as the source of exogenous complement (hSBA).

    Time frame: One month after the second vaccination (Day 91)

  2. Desirability Index for Each Vaccine Group, Based on Immunogenicity and Reactogenicity Parameters.

    The overall desirability index (DI) used to identify the optimal formulation of the combination vaccine was based on immunogenicity and reactogenicity parameters (on a scale of 0 to 1, with 0 for an undesirable response and 1 for a highly desirable response) as follows: Between-group ratios of hSBA GMTs were calculated, adjusted for prevaccination titer and center, against serogroups A, C, W, and Y (ABCWY+OMV group or ABCWY+qOMV group vs. Placebo/ACWY group) and against the 4 serogroup B test strains (ABCWY+OMV group or ABCWY+qOMV group vs. rMenB+OMV group). Reactogenicity was measured by the percentage of doses associated with severe local and systemic solicited AEs within 3 days following vaccination. Each immunogenicity and reactogenicity endpoint was assigned its own DI based on predefined desirability functions. The overall DI was calculated using the weighted geometric mean of the DI values of each of the ten parameters to derive an overall DI for each formulation.

    Time frame: One month after the second vaccination (Day 91)

Secondary outcomes

  1. Percentages of Subjects With hSBA Titers ≥ 1:8 Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

    Percentages of subjects with hSBA titers ≥ 1:8 against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine or one dose of MenACWY vaccine.

    Time frame: Day 1 and one month after second vaccination (Day 91)

  2. The hSBA GMTs Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

    The hSBA GMTs against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine, or one dose of MenACWY vaccine.

    Time frame: Day 1 and one month after the second vaccination (Day 91)

  3. Percentages of Subjects With hSBA Titers ≥ 1:5 and ≥ 1:8 Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

    The percentages of subjects with hSBA titers ≥ 1:5 and ≥ 1:8 against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.

    Time frame: Day 1 and one month after the second vaccination (Day 91)

  4. Percentages of Subjects With at Least 4-fold Increase in hSBA Titers Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

    The percentages of subjects with at least 4-fold increase in hSBA titers against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine. 4-fold increase is defined as follows; for subjects with a prevaccination hSBA \< 1:2, a postvaccination hSBA ≥ 1:8, for subjects with a prevaccination hSBA ≥ 1:2, at least a 4-fold increase.

    Time frame: One month after the second vaccination (Day 91)

  5. The hSBA GMTs Against N.Meningitidis serogroupB, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

    The hSBA GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.

    Time frame: Day 1 and one month after the second vaccination (Day 91)

  6. The Geometric Mean Ratio of Post vs Pre Vaccination GMTs Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

    The geometric mean ratio (GMR) of post vaccination versus pre vaccination GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.

    Time frame: One month after the second vaccination/prevaccination (Day 91/day 1)

  7. The Number of Subjects Reporting Solicited Adverse Events After Receiving Any Vaccination in This Study.

    The number of subjects reporting solicited local and systemic adverse events and other indicators of reactogenicity after vaccination with ABCWY+OMV, ABCWY+qOMV or rMenB+OMV or MenACWY.

    Time frame: Day 1 through day 7 after any vaccination

  8. The Number of Subjects Reporting Unsolicited Adverse Events After Receiving Any Vaccination in This Study.

    The number of subjects reporting unsolicited AEs after vaccination with ABCWY+OMV, ABCWY+qOMV, rMenB+OMV or MenACWY.

    Time frame: Throughout the study ( Day 1 to Day 241)

07

Results

Posted Sep 26, 2014

Participant flow

Participant flow — Overall Study
MilestoneABCWY+OMVABCWY+qOMVrMenB +OMVACWY
Started120121122121
Completed103100109107
Not completed17211314
Withdrew: Adverse event0010
Withdrew: Withdrawal by subject2632
Withdrew: Lost to follow-up1514810
Withdrew: Inappropriate enrollment0011
Withdrew: Protocol violation0101

Outcome measures

PrimaryPercentages of Subjects With a Seroresponse Against N.Meningitidis Serogroups A,C,W-135,Y, After Receiving Different Formulations of MenABCWY Combination Vaccine.

Non-inferiority of immune response of two doses of two different formulations of MenABCWY vaccine to a single dose of MenACWY vaccine as measured by the percentage of subjects with hSBA seroresponse against N.meningitidis serogroups A,C,W and Y. Seroresponse is defined as: 1. For subjects with a pre-vaccination hSBA titer \< 1:4, a post-vaccination hSBA titer ≥ 1:8; 2. For subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the prevaccination titer. Functional bactericidal antibodies directed against serogroups A,C,W,Y meningococci were measured with a serum bactericidal activity assay using human serum as the source of exogenous complement (hSBA).

Time frame:
One month after the second vaccination (Day 91)
Reported as:
Number · Percentages of subjects
Percentages of Subjects With a Seroresponse Against N.Meningitidis Serogroups A,C,W-135,Y, After Receiving Different Formulations of MenABCWY Combination Vaccine.
Percentages of subjectsABCWY+OMVABCWY+qOMVACWY
Men A90 (81 to 95)92 (83 to 97)73 (62 to 83)
Men C95 (89 to 99)93 (85 to 97)63 (51 to 74)
Men W-13580 (69 to 88)84 (73 to 91)65 (52 to 77)
Men Y92 (83 to 97)90 (80 to 96)75 (62 to 85)
Statistical analysis
  • ABCWY+OMV vs ACWY · Group difference % (abcwy+omv - acwy): 16 · 95% CI 5 to 29
  • ABCWY+OMV vs ACWY · Group difference % (abcwy+omv - acwy): 32 · 95% CI 21 to 44
  • ABCWY+OMV vs ACWY · Group difference % (abcwy+omv - acwy): 15 · 95% CI 0 to 30
  • ABCWY+OMV vs ACWY · Group difference % (abcwy+omv - acwy): 18 · 95% CI 5 to 31
  • ABCWY+qOMV vs ACWY · Group difference % (abcwy+qomv - acwy): 18 · 95% CI 7 to 30
  • ABCWY+qOMV vs ACWY · Group difference % (abcwy+qomv - acwy): 30 · 95% CI 18 to 42
  • ABCWY+qOMV vs ACWY · Group difference % (abcwy+qomv - acwy): 19 · 95% CI 4 to 33
  • ABCWY+qOMV vs ACWY · Group difference % (abcwy+qomv - acwy): 15 · 95% CI 3 to 29
PrimaryDesirability Index for Each Vaccine Group, Based on Immunogenicity and Reactogenicity Parameters.

The overall desirability index (DI) used to identify the optimal formulation of the combination vaccine was based on immunogenicity and reactogenicity parameters (on a scale of 0 to 1, with 0 for an undesirable response and 1 for a highly desirable response) as follows: Between-group ratios of hSBA GMTs were calculated, adjusted for prevaccination titer and center, against serogroups A, C, W, and Y (ABCWY+OMV group or ABCWY+qOMV group vs. Placebo/ACWY group) and against the 4 serogroup B test strains (ABCWY+OMV group or ABCWY+qOMV group vs. rMenB+OMV group). Reactogenicity was measured by the percentage of doses associated with severe local and systemic solicited AEs within 3 days following vaccination. Each immunogenicity and reactogenicity endpoint was assigned its own DI based on predefined desirability functions. The overall DI was calculated using the weighted geometric mean of the DI values of each of the ten parameters to derive an overall DI for each formulation.

Time frame:
One month after the second vaccination (Day 91)
Reported as:
Number · Desirability index
Desirability Index for Each Vaccine Group, Based on Immunogenicity and Reactogenicity Parameters.
Desirability indexABCWY+OMVABCWY+qOMV
Desirability Index for Each Vaccine Group, Based on Immunogenicity and Reactogenicity Parameters.0.3060.325
SecondaryPercentages of Subjects With hSBA Titers ≥ 1:8 Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

Percentages of subjects with hSBA titers ≥ 1:8 against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine or one dose of MenACWY vaccine.

Time frame:
Day 1 and one month after second vaccination (Day 91)
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥ 1:8 Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
Percentages of subjectsABCWY+OMVABCWY+qOMVACWY
Men A (Day 1)8 (3 to 15)6 (2 to 13)1 (0.033 to 7)
Men A (Day 91)93 (86 to 97)95 (88 to 99)73 (62 to 83)
Men C (Day 1)35 (25 to 46)35 (25 to 46)32 (21 to 43)
Men C (Day 91)99 (94 to 100)100 (96 to 100)83 (73 to 91)
Men W-135 (Day 1)66 (55 to 76)58 (47 to 69)51 (39 to 64)
Men W-135 (Day 91)100 (95 to 100)100 (95 to 100)89 (79 to 96)
Men Y (Day 1)18 (11 to 28)15 (8 to 25)8 (3 to 17)
Men Y (Day 91)97 (89 to 100)97 (90 to 100)82 (70 to 90)
SecondaryThe hSBA GMTs Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

The hSBA GMTs against N.meningitidis serogroups A,C,W-135 and Y, after two doses of either ABCWY+OMV or ABCWY+qOMV combination vaccine, or one dose of MenACWY vaccine.

Time frame:
Day 1 and one month after the second vaccination (Day 91)
Reported as:
Geometric mean · Titers
The hSBA GMTs Against N.Meningitidis Serogroups A,C,W-135 and Y, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
TitersABCWY+OMVABCWY+qOMVACWY
Men A (Day 1)1.57 (1.28 to 1.92)1.32 (1.07 to 1.63)1.33 (1.08 to 1.65)
Men A (Day 91)71 (49 to 102)77 (53 to 111)45 (31 to 65)
Men C (Day 1)4.15 (3.02 to 5.69)3.72 (2.69 to 5.12)3.93 (2.84 to 5.45)
Men C (Day 91)214 (148 to 309)187 (129 to 272)55 (38 to 80)
Men W-135 (Day 1)14 (8.88 to 22)10 (6.45 to 16)6.58 (4.11 to 11)
Men W-135 (Day 91)239 (178 to 322)288 (214 to 389)65 (48 to 90)
Men Y (Day 1)2.01 (1.52 to 2.66)1.91 (1.43 to 2.53)1.52 (1.14 to 2.04)
Men Y (Day 91)149 (95 to 234)129 (83 to 201)46 (29 to 72)
SecondaryPercentages of Subjects With hSBA Titers ≥ 1:5 and ≥ 1:8 Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

The percentages of subjects with hSBA titers ≥ 1:5 and ≥ 1:8 against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.

Time frame:
Day 1 and one month after the second vaccination (Day 91)
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥ 1:5 and ≥ 1:8 Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
Percentages of subjectsABCWY+OMVABCWY+qOMVrMenB +OMV
M14459 (Day 1; hSBA ≥1:5)9 (4 to 17)4 (1 to 10)5 (2 to 12)
M14459 (Day 91; hSBA ≥1:5)64 (53 to 74)71 (60 to 80)82 (72 to 89)
M01-0240364 (Day 1; hSBA ≥1:5)3 (1 to 9)14 (8 to 24)4 (1 to 11)
M01-0240364 (Day 91; hSBA ≥1:5)80 (70 to 88)80 (70 to 88)93 (86 to 98)
NZ 98/254 (Day 1; hSBA ≥1:5)3 (1 to 10)1 (0.03 to 6)3 (1 to 9)
SecondaryPercentages of Subjects With at Least 4-fold Increase in hSBA Titers Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

The percentages of subjects with at least 4-fold increase in hSBA titers against four different strains of N.meningitidis serogroup B, after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine. 4-fold increase is defined as follows; for subjects with a prevaccination hSBA \< 1:2, a postvaccination hSBA ≥ 1:8, for subjects with a prevaccination hSBA ≥ 1:2, at least a 4-fold increase.

Time frame:
One month after the second vaccination (Day 91)
Reported as:
Number · Percentages of subjects
Percentages of Subjects With at Least 4-fold Increase in hSBA Titers Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
Percentages of subjectsABCWY+OMVABCWY+qOMVrMenB+OMV
M1445956 (45 to 67)62 (51 to 73)75 (65 to 83)
M01-024036479 (69 to 87)70 (59 to 79)88 (79 to 94)
NZ98/25447 (36 to 58)48 (37 to 59)76 (66 to 84)
M07-024108428 (19 to 38)25 (16 to 36)42 (32 to 53)
SecondaryThe hSBA GMTs Against N.Meningitidis serogroupB, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

The hSBA GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.

Time frame:
Day 1 and one month after the second vaccination (Day 91)
Reported as:
Geometric mean · Titers
The hSBA GMTs Against N.Meningitidis serogroupB, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
TitersABCWY+OMVABCWY+qOMVrMenB +OMV
M14459 (Day 1)1.32 (1.09 to 1.59)1.15 (0.95 to 1.4)1.26 (1.04 to 1.53)
M14459 (Day 91)9.24 (6.19 to 14)11 (7.51 to 17)17 (11 to 25)
M01-0240364 (Day 1)1.08 (0.82 to 1.42)1.72 (1.29 to 2.28)1.14 (0.86 to 1.51)
M01-0240364 (Day 91)55 (33 to 93)48 (28 to 83)118 (69 to 202)
NZ 98/254 (Day 1)1.2 (1.03 to 1.39)1.1 (0.94 to 1.28)1.21 (1.04 to 1.42)
NZ 98/254 (Day 91)8.68 (5.91 to 13)7.88 (5.3 to 12)19 (13 to 27)
M07-0241084 (Day 1)2.55 (1.86 to 3.49)2.45 (1.76 to 3.4)2.13 (1.54 to 2.94)
M07-0241084 (Day 91)7.24 (5.4 to 9.71)6.26 (4.63 to 8.46)12 (8.83 to 16)
SecondaryThe Geometric Mean Ratio of Post vs Pre Vaccination GMTs Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.

The geometric mean ratio (GMR) of post vaccination versus pre vaccination GMTs against N.meningitidis serogroup B after two doses of ABCWY+OMV, ABCWY+qOMV or rMenB+OMV vaccine.

Time frame:
One month after the second vaccination/prevaccination (Day 91/day 1)
Reported as:
Geometric mean · Ratio
The Geometric Mean Ratio of Post vs Pre Vaccination GMTs Against N.Meningitidis Serogroup B, After Vaccination With Different Formulations of MenABCWY Combination Vaccine.
RatioABCWY+OMVABCWY+qOMVrMenB+OMV
M144597.32 (4.89 to 11)9.41 (6.19 to 14)14 (9.01 to 21)
M01-024036448 (27 to 83)30 (17 to 54)98 (56 to 173)
NZ 98/2547.44 (5.06 to 11)6.91 (4.64 to 10)16 (11 to 23)
M07-02410842.94 (2.15 to 4.02)2.59 (1.88 to 3.58)5.16 (3.76 to 7.08)
SecondaryThe Number of Subjects Reporting Solicited Adverse Events After Receiving Any Vaccination in This Study.

The number of subjects reporting solicited local and systemic adverse events and other indicators of reactogenicity after vaccination with ABCWY+OMV, ABCWY+qOMV or rMenB+OMV or MenACWY.

Time frame:
Day 1 through day 7 after any vaccination
Reported as:
Number · Participants
The Number of Subjects Reporting Solicited Adverse Events After Receiving Any Vaccination in This Study.
ParticipantsABCWY+OMVABCWY+qOMVrMenB+OMVACWY
Injection site erythema57537230
Injection site induration46524624
Injection site pain989610750
Chills18212912
Nausea1525308
Fatigue32475230
Myalgia65676738
Arthralgia2023257
Headache37405329
Rash6846
Loss of appetite17222412
Fever ( >= 38C )7561
Medically attended fever2000
Prophylactic use of antipyretic1714167
Therapeutic use of antipyretic18262710
SecondaryThe Number of Subjects Reporting Unsolicited Adverse Events After Receiving Any Vaccination in This Study.

The number of subjects reporting unsolicited AEs after vaccination with ABCWY+OMV, ABCWY+qOMV, rMenB+OMV or MenACWY.

Time frame:
Throughout the study ( Day 1 to Day 241)
Reported as:
Number · Participants
The Number of Subjects Reporting Unsolicited Adverse Events After Receiving Any Vaccination in This Study.
ParticipantsABCWY+OMVABCWY+qOMVrMenB+OMVACWY
Any AEs (from day 1 to 30)36364531
At least possibly related AEs (day 1 to 30)1210166
Any AEs (day 31 to 60 or study termination)22292926
At least poss.rel.AEs(day 31 to 60 or study term.)0100
Any AE from day 1 to 9151556650
At least poss.rel.AEs(day 1 to 91)1310166
Medically attended AEs (day 92 to 241)26243031
possibly related med.attend.AEs (day 92-241)0000
SAEs (Day 1 to Day 241)2213
Possibly/probably related SAEs0000
AEs leading to withdrawal (Day 1 to Day 241)0020
Deaths (Day 1 to Day 241)0000
Post-hocPercentages of Subjects With hSBA Titers ≥ 1:5 Against N.Meningitidis Serogroup B Strains 44/76 and 5/99

Percentages of Subjects With hSBA Titers ≥ 1:5 Against N.Meningitidis Serogroup B strains 44/76 and 5/99 at one month after second vaccination are calculated

Time frame:
At baseline and one month after second vaccination (Day 91)
Reported as:
Number · Percentage of subjects
Percentages of Subjects With hSBA Titers ≥ 1:5 Against N.Meningitidis Serogroup B Strains 44/76 and 5/99
Percentage of subjectsABCWY+OMVABCWY+qOMVrMenB +OMV
44/76- Baseline6 (2 to 12)7 (3 to 15)7 (2 to 14)
44/76- 1 month after second dose100 (96 to 100)99 (94 to 100)98 (92 to 100)
5/99- Baseline11 (6 to 20)15 (8 to 25)16 (9 to 25)
5/99- 1 month after second dose99 (94 to 100)99 (94 to 100)98 (92 to 100)

Adverse events

Collected over Solicited AEs were collected from Day 1to Day 7; unsolicited AEs and SAEs were collected throughout the study period (Day 1 to Day 241).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABCWY+OMV—2/120 (1.7%)104/120 (86.7%)
ABCWY+qOMV—2/120 (1.7%)104/120 (86.7%)
rMenB +OMV—1/120 (0.8%)111/120 (92.5%)
ACWY—3/109 (2.8%)87/109 (79.8%)
Most frequent serious events
Most frequent serious events
EventABCWY+OMVABCWY+qOMVrMenB +OMVACWY
ABDOMINAL PAINGastrointestinal disorders0/1200/1200/1201/109
SPERMATOCELEReproductive system and breast disorders0/1200/1200/1201/109
SLEEP APNOEA SYNDROMERespiratory, thoracic and mediastinal disorders0/1200/1200/1201/109
GASTROENTERITISInfections and infestations1/1200/1200/1200/109
PERTUSSISInfections and infestations0/1201/1200/1200/109
PNEUMONIAInfections and infestations1/1200/1200/1200/109
URINARY TRACT INFECTIONInfections and infestations0/1201/1200/1200/109
CONVULSIONNervous system disorders0/1200/1201/1200/109
ABNORMAL BEHAVIOURPsychiatric disorders0/1201/1200/1200/109
Most frequent other events
Showing 10 of 19
Most frequent other events
EventABCWY+OMVABCWY+qOMVrMenB +OMVACWY
Injection site PainGeneral disorders100/12097/120107/12056/109
Injection site ErythemaGeneral disorders59/12053/12072/12032/109
MyalgiaMusculoskeletal and connective tissue disorders65/12067/12067/12039/109
HeadacheNervous system disorders38/12041/12053/12032/109
FatigueGeneral disorders33/12047/12052/12032/109
Injection site IndurationGeneral disorders47/12052/12046/12025/109
NauseaGastrointestinal disorders15/12025/12031/1209/109
ChillsGeneral disorders19/12022/12029/12012/109
ArthralgiaMusculoskeletal and connective tissue disorders22/12024/12025/1208/109
Decreased appetiteMetabolism and nutrition disorders17/12022/12024/12012/109

Baseline characteristics

Anaysis was done on the All Enrolled Population, ie, all subjects who signed an informed consent/assent, undergone screening procedure(s) and were randomized.

Age, Continuous
Age, Continuous(years)ABCWY+OMVABCWY+qOMVrMenB +OMVACWYTotal
Mean14.7 ± 4.715.1 ± 4.915.3 ± 4.915.0 ± 5.115.0 ± 4.9
Sex: Female, Male
Sex: Female, Male(Participants)ABCWY+OMVABCWY+qOMVrMenB +OMVACWYTotal
Female61686064253
Male59536257231
08

Study locations

13 sites
  • Alabama Clinical Therapeutics, 806 St. Vincent's Drive, Suite 615
    Birmingham, Alabama 35205, United States
  • Madera Family Medical Group,1111 West 4th Street
    Madera, California 93637, United States
  • Center for Clinical Trials LLC, 16660 Paramount Blvd, Suite 301
    Paramount, California 90723, United States
  • Kentucky Pediatric/Adult Research, 201 south 5th street
    Bardstown, Kentucky 40004, United States
  • Bluegrass Clinical Research Inc.5512 Bardstown Road, Suite 2
    Louisville, Kentucky 40291, United States
  • Ohio Pediatric Research Association, 7371 Brandt Pike, Suite C
    Huber Heights, Ohio 45424, United States
  • Ohio Pediatric Research Association, 1775 Delco Park Drive
    Kettering, Ohio 45420, United States
  • Focus Research Group,201 Signature Place
    Lebanon, Tennessee 37087, United States
  • Specjalistyczna Przychodnia Lekarska Internistyczno-Pediatryczna,,Juniperus"s.c, ul.Kościuszki 41
    Izabelin (Warszawa), 05-080, Poland
  • NZOZ HIPOKRATES II.sp.zo.o, ul.Pachonskiego 12
    Kraków, 31-223, Poland
  • NZOZ PRAKTIMED Sp.zo.o, ul.Strzelców 15
    Kraków, 31-422, Poland
  • Klinika Pediatrii Centrum Medycznego Kształcenia PodyplomowegoSzpital Bielański, ul. Cegłowska 80
    Warszawa, 01-809, Poland
  • Katedra i Klinika Pediatrii i Chorób Infekcyjnych, ul.O.Bujwida 44
    Wrocław, 50-354, Poland
09

References and documents

Publications

  • Szenborn L, Block SL, Jackowska T, Konior R, D'Agostino D, Smolenov I, Toneatto D, Welsch JA. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study. Pediatr Infect Dis J. 2018 May;37(5):475-482. doi: 10.1097/INF.0000000000001896. PubMed 29329168 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Oct 2011 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2011
First posted
Jan 7, 2011
Start
Aug 2011
Primary completionActual
Oct 2011
CompletionActual
Sep 2012
Results first posted
Sep 26, 2014
Last update
Jun 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01272180
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Jan 7, 2011
Start date
Aug 2011
Primary completion
Oct 2011
Completion
Sep 2012
Results posted
Sep 26, 2014
Last update
Jun 16, 2020

Study contacts

Novartis Vaccines
study chair · Novartis Vaccines
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion